Paper Details

  1. Home
  2. Paper Details

Evidence-based treatment algorithm for mild to moderate Crohn's disease.

Author: SandbornWilliam J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

Sulfasalazine, budesonide, and oral corticosteroids are effective treatments for mild to moderate Crohn’s disease, and typically last 8-16 weeks. For patients whose symptoms return within 6-12 months after stopping treatment, another round of treatment is recommended, followed by long-term treatment with an immunosuppressant medication. Long-term treatment with budesonide may be an alternative for those who have a relapse within 6-12 months after stopping treatment or for those who are dependent on prednisone.
Paper Details　
Original Abstract of the Article :
Therapies demonstrated to be effective in randomized, controlled trials for induction of remission in patients with mildly to moderately active Crohn's disease include sulfasalazine, budesonide, and oral corticosteroids administered for 8-16 wk. Patients who relapse within 6-12 months after disconti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.amjgastroenterol.2003.10.007

データ提供：米国国立医学図書館（NLM）

Navigating Mild to Moderate Crohn's Disease: A Treatment Algorithm

This study delves into the realm of gastroenterology, exploring the effective management of mild to moderate Crohn's disease. The study outlines a structured treatment algorithm, drawing on the results of randomized controlled trials. The algorithm emphasizes the use of therapies like sulfasalazine, budesonide, and oral corticosteroids for inducing remission. For patients experiencing relapses, the algorithm recommends another cycle of induction therapy followed by maintenance therapy with immunosuppressive agents such as azathioprine, 6-mercaptopurine, or methotrexate. The study also proposes budesonide as an alternative maintenance therapy for specific patient groups. This research aims to provide a clear roadmap for managing Crohn's disease, ensuring consistent and effective treatments.

A Roadmap for Crohn's Disease Management

This treatment algorithm offers a structured approach to managing Crohn's disease. The study's findings demonstrate the effectiveness of various therapies in inducing remission and preventing relapses. Think of this algorithm as a desert caravan route, guiding patients through the challenging terrain of Crohn's disease towards better health.

Improved Quality of Life for Crohn's Patients

This treatment algorithm holds the potential to improve the quality of life for those with Crohn's disease. By providing a clear treatment strategy, the algorithm helps healthcare providers to effectively manage the disease, reducing the frequency and severity of relapses. This can help patients live more fulfilling lives, free from the limitations imposed by Crohn's. Imagine a thriving oasis, where patients can find relief from the symptoms of Crohn's, allowing them to enjoy life more fully.

Dr.Camel's Conclusion

This treatment algorithm offers a comprehensive approach to managing mild to moderate Crohn's disease. By providing clear guidelines for induction and maintenance therapy, the algorithm offers the potential to improve the lives of those affected by this chronic condition. As a research camel, I'm always on the lookout for new solutions to challenging medical conditions, and this study is a testament to the ongoing efforts in this field.
Date :
  1. Date Completed 2004-02-12
  2. Date Revised 2019-11-08
Further Info :

Pubmed ID

14697912

DOI: Digital Object Identifier

10.1016/j.amjgastroenterol.2003.10.007

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.